Lurie Cancer Center Receives $4.27 Million from the Department of Defense for Breast Cancer Research

Publication
Article
OncologyONCOLOGY Vol 11 No 1
Volume 11
Issue 1

Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Center of Northwestern University, announced that the Center has received a 4-year grant in the amount of $4.27 million from the US Army Medical Research and Materiel

Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Centerof Northwestern University, announced that the Center has received a 4-yeargrant in the amount of $4.27 million from the US Army Medical Researchand Materiel Command for a project entitled, "Increasing Access toModern Multidisciplinary Breast Cancer Care."

The principal investigator of the project is Monica Morrow, MD, directorof the Lurie Cancer Center's Clinical Breast Cancer Research Program; associateprofessor, Department of Surgery, Northwestern University Medical School;and director of the Lynn Sage Comprehensive Breast Center at NorthwesternMemorial Hospital.

The award provides funds for eight research projects that focus on accessto breast cancer care by minority women; education of minority women andnonphysician providers who have contact with the medically underserved;dietary intervention to reduce cancer risk; methods to increase minorityparticipation in clinical trials; and the cost-effectiveness of new technologies.

The Robert H. Lurie Cancer Center of Northwestern University, a NationalCancer Institute-designated clinical cancer center, is the focus of cancerresearch, education, and patient care at Northwestern University. The LurieCancer Center coordinates clinical research and cancer patient care programsat the teaching affiliates of the Northwestern University Medical Schooland, through the Northwestern Healthcare Network, is associated with thecancer programs at nine hospitals in the Chicago area.

Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.